BIOGAIA Aktie

 

Often considered as our “second brain”, the human gut and its resident microbiota play a crucial bidirectional role communicating the brain (central nervous system) with the gut (enteric nervous system), in what is called the microbiota-gut-brain axis. Researchers of University of Gothenburg and BioGaia AB (NASDAQ: BIOG) have identified that specific bacteria present in the gut can produce an important bioactive substance of the microbiota-gut-brain axis: serotonin. Serotonin is best known as a neurotransmitter in the brain, but over 90 percent of the body's serotonin is found in the...

THIRD QUARTER 2025 Net sales amounted to SEK 326.6 million (304.0), an increase of SEK 22.7 million, or an increase of 7% (excluding foreign exchange effects an increase of 14%). Net sales in the Pediatrics segment amounted to SEK 242.6 million (225.8), an increase of 7% (excluding foreign exchange effects an increase of 14%). Net sales in the Adult Health segment amounted to SEK 81.6 million (76.6), an increase of 6% (excluding foreign exchange effects an increase of 13%). Operating expenses amounted to SEK 156.5 million (180.9), a decrease of SEK 24.4 million (13%). Operating...

We are proud to announce that the scientific rationale and identification of our newly patented strain, Limosilactobacillus reuteri BG-R46®, has been published in the prestigious journal, Beneficial Microbes. This next-generation strain will be featured in our upcoming baby drops product. Developed by BioGaia AB (NASDAQ: BIOG) and a research team at the Swedish University of Agricultural Sciences in Uppsala, led by Prof. Stefan Roos, who also oversees BioGaia's preclinical studies. BG-R46® is an evolved derivative of L. reuteri DSM 17938, obtained through selective exposure to bile, a...

BioGaia's (NASDAQ: BIOG) financial report for the third quarter of 2025 will be published at approximately 8:00 AM CEST on October 22, 2025. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website (https://www.biogaiagroup.com/investors/financial-reports/). CEO Theresa Agnew and CFO Alexander Kotsinas will comment on the report and take questions at a live audiocast at 9:30 AM CEST. To join the audiocast with teleconference and ask a...

We are thrilled to launch BioGaia Prodentis® FRESH BREATH lozenges, a microbiome-friendly dental probiotic with zinc that both supports healthy teeth and gums and promotes instant and long-lasting fresh breath. This innovation expands BioGaia's specialized oral care portfolio of products, adding yet another probiotic format that is the world's most researched for oral health. BioGaia Prodentis® FRESH BREATH has dual action protection to fight against bad breath. It combines zinc to neutralize odor-causing compounds and patented probiotics to naturally battle the bad breath-causing...

BioGaia AB (NASDAQ: BIOG) establishes its own distribution in Germany and Austria through a newly formed subsidiary in Germany which will distribute and market BioGaia's products in both Germany and Austria under the company and brand name “BiGaia” (due to current market reasons the company and brand name has been BiGaia and not BioGaia). This strategic decision to go direct, effective from early 2026, aligns with BioGaia's overarching strategy to expand through direct market presence. At the same time, BioGaia will be concluding its collaboration with the previous local distribution...

In a recent study, published in the European Journal of Pediatrics, BioGaia´s patented bacteria strain, Limosilactobacillus reuteri DSM 17938, was shown to prevent antibiotic-associated diarrhea (AAD) in children. The prospective, multi-center, randomized, placebo-controlled clinical trial, known as the PEARL Study, investigated the effect of L. reuteri DSM 17938 in children aged between 6 months and 10 years, receiving amoxicillin and clavulanic acid to treat acute otitis media or acute rhinosinusitis. Results showed a statistically significant reduction in the incidence of AAD in...

Mauricio Graber, newly elected chairman of the board has entered into an agreement to purchase 735,754 class B shares from Anatom Holding, BioGaia's anchor shareholder. The significant investment underlines Mauricio Graber's commitment to actively supporting the company's future development and its management team and creates a strong alignment of interests with all stakeholders. Following settlement of the transaction, Anatom will hold 1,776,758 A shares and 4,845,021 B shares (6.5% of the total number of shares and 18.1% of the total number of votes). About Mauricio Graber...

At an extraordinary general meeting of BioGaia AB (publ) on 22 August 2025, it was resolved to elect Mauricio Graber as new board member and chairman of the board, following Peter Rothschild's decision to resign as board member and chairman. Follow us: Subscribe to BioGaia press releases here (https://www.biogaiagroup.com/newsroom/subscribe-to-press-releases) LinkedIn here (https://www.linkedin.com/company/biogaia-ab/) Contacts: Theresa Agnew, President and CEO Email: Theresa.P.Agnew@biogaia.com Phone: +46(0)8 555 293 00 Alexander Kotsinas, CFO Email: Alexander.Kotsinas@...

BioGaia AB (publ) will hold an Extraordinary General Meeting at 16 p.m. on 22 August 2025, at Klara Konferens & Happynings på Klara Strand, Klarabergsviadukten 90, in Stockholm. The doors will be opened for registration at 3:30 p.m. Right to participate In order to participate in the Extraordinary General Meeting (EGM), shareholders must be recorded in the register of shareholders maintained by Euroclear Sweden AB relating to the circumstances on 14 August 2025 and must provide notice of participation to the company no later than 18 August 2025. Notification can be made by mail to...

SECOND QUARTER 2025 Net sales amounted to SEK 404.7 million (384.1), an increase of SEK 20.6 million, or an increase of 5% (excluding foreign exchange effects an increase of 13.2%). Net sales in the Pediatrics segment amounted to SEK 310.1 million (304.8), an increase of 2% (excluding foreign exchange effects an increase of 9%). Net sales in the Adult Health segment amounted to SEK 89.8 million (78.2), an increase of 15% (excluding foreign exchange effects an increase of 23%). Operating expenses amounted to SEK 185.5 million (148.7), an increase of SEK 36.9 million (25%). Operating...

As interest in biotics[1] and their wide range of health applications continues to grow, BioGaia is proud to announce the launch of a subsidiary company, BioGaia New Sciences AB, dedicated to exploring opportunities in microbiome friendly and biotics-containing products beyond BioGaia's current core focus areas: gut health, immune health, and oral health. The first area for the new company will be skin health, a natural next step, given the parallels between skin and gut microbiomes. The skin microbiome, much like the gut microbiome, plays a vital role in overall health. In early life,...

BioGaia AB's Nomination Committee for the Annual General Meeting 2026 has been appointed based on the ownership structure as of June 30, 2025. The Nomination Committee for the Annual General Meeting 2026 has been formed in accordance with the decision of the Annual General Meeting 2025. The Nomination Committee consists of Alexander Kahane (Chairman of the Nomination Committee), appointed by the largest shareholder Anatom Holding AG, Jannis Kitsakis, appointed by Fjärde AP-Fonden, Thomas Brown, Premier Miton Investors, and Julie Gaskjenn, Cargill Inc. In addition, Peter Rothschild is a...

BioGaia's (NASDAQ: BIOG) financial report for the second quarter of 2025 will be published at approximately 8:00 AM CEST on July 18, 2025. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website (https://www.biogaiagroup.com/investors/financial-reports/). CEO Theresa Agnew and CFO Alexander Kotsinas will comment on the report and take questions at a live audiocast at 9:30 AM CEST. To join the audiocast with teleconference and ask a...

The number of votes in BioGaia decreased during May as a result of the conversion of a total of 1,038,202 Class A shares into 1,038,202 Class B shares. The conversion was carried out based on the provision in the Articles of Association, introduced at the Annual General Meeting on May 7, 2025, allowing Class A shareholders to request conversion of Class A shares into Class B shares. As of May 30, 2025, the total number of shares in BioGaia amounts to 101,162,310 of which 2,665,138 are Class A shares with ten votes each and 98,497,172 are Class B shares with one vote each, totaling 125,...

BioGaia has been recognized by TIME Magazine´s and Statista's prestigious list of the World's Top 500 Companies Pairing Growth with Environmental Stewardship. This recognition highlights BioGaia's commitment to combining strong business performance with responsible environmental practices. The ranking evaluates 5,000 global companies based on three core dimensions: revenue growth, financial stability, and environmental impact. The environmental assessment focuses on carbon emissions across Scope 1, 2, and 3, both in total and relative to revenue and industry peers. Other factors such as...

The Annual General Meeting of BioGaia AB (publ) on 7 May 2025 voted, among other things, to approve the following resolutions: - adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet - discharge from liability for the Board members and the CEO - a dividend of SEK 1.95 per share plus an extra dividend of SEK 4.95 per share resulting in a total dividend of SEK 6.90 per share and a grant of SEK 5.0 million to “The Foundation to Prevent Antibiotic Resistance” that was founded by BioGaia in 2017. The purpose of the...

FIRST QUARTER 2025 Net sales amounted to SEK 366.3 million (369.8), a decrease of SEK 3.5 million, or a decrease of 1% (excluding foreign exchange effects a decrease of 3.6%). Net sales in the Pediatrics segment amounted to SEK 269.9 million (292.3), a decrease of 8% (excluding foreign exchange effects a decrease of 10%). Net sales in the Adult Health segment amounted to SEK 94.6 million (74.8), an increase of 26% (excluding foreign exchange effects an increase of 23%). Operating expenses amounted to SEK 171.2 million (122.6), an increase of SEK 48.6 million (40%). Operating...

BioGaia AB (NASDAQ: BIOG) is expanding its global footprint by establishing direct sales in the Netherlands initially through an online approach. BioGaia will launch sales of its products on the major local marketplaces, Bol.com and Amazon.nl. This initiative supports BioGaia's long-term strategy to expand through direct sales and bring its clinically proven probiotics closer to consumers. The Netherlands is one of the last countries in Europe where our products are not yet available through our own direct sales or a distributor. Given the strong potential and increasing interest in...

BioGaia's (NASDAQ: BIOG) financial report for the first quarter of 2025 will be published at approximately 8:00 AM CEST on May 7, 2025. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website (https://www.biogaiagroup.com/investors/financial-reports/). CEO Theresa Agnew and CFO Alexander Kotsinas will comment on the report and take questions at a live audiocast at 9:30 AM CEST. To join the audiocast with teleconference and ask a...